These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23647720)

  • 1. Clinical experience with BIAsp 30: results from the Indonesian cohort of the international A₁chieve study.
    Soewondo P; Pramono RB; Langi YA; Soetedjo NN; Kshanti IA
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S54-9. PubMed ID: 23647720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching from biphasic human insulin to biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN subgroup of the A₁chieve study.
    Hussein Z; Lim-Abrahan MA; Jain AB; Goh SY; Soewondo P
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S24-9. PubMed ID: 23647714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Indonesian cohort of the A₁chieve study.
    Soewondo P; Lindarto D; Wibisono S; Renaldi O; Dalem-Pemayun TG
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S41-6. PubMed ID: 23647718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN cohort of the A₁chieve study.
    Lim-Abrahan MA; Jain AB; Bebakar WM; Seah D; Soewondo P
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S3-9. PubMed ID: 23647715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and effectiveness of biphasic insulin aspart 30 in a Bangladeshi subgroup of type 2 diabetic patients switched from biphasic human insulin 30: a sub-analysis of the A₁chieve study.
    Latif ZA; Pathan MF; Siddiqui MN; Sobhan MJ; Rahman MM; Ashrafuzzaman SM
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S30-4. PubMed ID: 23647716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Filipino cohort of the A₁chieve study.
    Lim-Abrahan MA; Yu-Gan S; Jain AB; Sobrepena LM; Racho VA
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S35-40. PubMed ID: 23647717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience with insulin detemir: results from the Indonesian cohort of the international A₁chieve study.
    Soewondo P; Kshanti IA; Pramono RB; Langi YA; Dalem-Pemayun TG
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S47-53. PubMed ID: 23647719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and effectiveness of insulin aspart in type 2 diabetic patients: results from the ASEAN cohort of the A₁chieve study.
    Bebakar WM; Lim-Abrahan MA; Jain AB; Seah D; Soewondo P
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S17-23. PubMed ID: 23647713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initiating or switching to biphasic insulin aspart 30 in type 2 diabetes patients from Algeria: a sub-analysis of the A₁chieve study.
    Lezzar A; Ayad F; Dahaoui A; Salah-Mansour A; Berrouiguet AY
    Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S37-44. PubMed ID: 23958570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of achieving HbA(1c) <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study.
    Valensi P; Shaban J; Benroubi M; Kawamori R; Borzì V; Shah S; Wenying Y; Prusty V; Hansen JB; Gumprecht J;
    Curr Med Res Opin; 2013 Jun; 29(6):601-9. PubMed ID: 23488447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Starting or switching to biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes: a multicenter, observational, primary care study conducted in Finland.
    Mäkelä JK; Schmüser C; Askonen K; Saukkonen T
    Diabetes Res Clin Pract; 2012 Jan; 95(1):10-8. PubMed ID: 22078072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 twice daily in insulin-experienced Japanese subjects with uncontrolled type 2 diabetes: Subgroup analysis of a Pan-Asian, treat-to-target Phase 3 Trial.
    Taneda S; Hyllested-Winge J; Gall MA; Kaneko S; Hirao K
    J Diabetes; 2017 Mar; 9(3):243-247. PubMed ID: 27059529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
    Kaneko S; Chow F; Choi DS; Taneda S; Hirao K; Park Y; Andersen TH; Gall MA; Christiansen JS;
    Diabetes Res Clin Pract; 2015 Jan; 107(1):139-47. PubMed ID: 25498130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Composite cardiovascular risk and BMI affected comparative profiles of BIAsp 30 + metformin vs BIAsp 30 monotherapy: a MERIT post-hoc analysis.
    Guo L; Chang B; Chen L; Yang L; Liu Y; Feng B; He Q
    Sci Rep; 2021 Feb; 11(1):4131. PubMed ID: 33602996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and effectiveness of biphasic insulin aspart 30 (Biasp 30) in people with type 2 diabetes mellitus in the pakistani population: results from the A1chieve study.
    Hassan MI; Aamir AH; Miyan Z; Siddiqui LA; Qureshi MS; Shaikh MZ
    J Pak Med Assoc; 2012 Sep; 62(9):929-36. PubMed ID: 23139978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of biphasic insulin aspart 70/30 in type 2 diabetes patients of different race or ethnicity (INITIATEplus trial).
    Trippe BS; Shepherd MD; Coulter FC; Bhargava A; Brett J; Chu PL; Oyer DS
    Curr Med Res Opin; 2012 Jul; 28(7):1203-11. PubMed ID: 22509859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes.
    Christiansen JS; Niskanen L; Rasmussen S; Johansen T; Fulcher G
    J Diabetes; 2016 Sep; 8(5):720-8. PubMed ID: 26612062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initiating therapy or switching to biphasic insulin aspart improves glycaemic control in type 2 diabetes: an Indian experience from the A1chieve study.
    Kumar A; Sharma SK; Rajput R; Unnikrishnan AG
    J Assoc Physicians India; 2013 Jan; 61(1 Suppl):16-20. PubMed ID: 24482982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin-The Sit2Mix trial.
    Linjawi S; Sothiratnam R; Sari R; Andersen H; Hiort LC; Rao P
    Prim Care Diabetes; 2015 Oct; 9(5):370-6. PubMed ID: 25488587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Criteria influencing the choice of starting insulin regimen in patients with type 2 diabetes in routine clinical practice: baseline data from the Algerian cohort of the A₁chieve study.
    Malek R; Arbouche Z; Bachaoui M; Zinai S; Dahaoui A; Senoussaoui S; Salah-Mansour A
    Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S45-9. PubMed ID: 23958572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.